THANK YOU - for all those who made our first-ever #GRxBiosims virtual conference a success.

Health Care Savings, State by State

The average state saved $6.1 billion from the use of generic drugs in 2019. How much did your state save?

Read Blog
Celebrating 10 Years of Biosimilars

Help reflect on these last 10 years and discuss how to make the next 10 years even better by trying our new Instagram lens and sharing your selfie with #b10similars in social media.

Learn More
Generic Savings Add Up for Patients with Cancer and Other Conditions

No matter what condition you or your family members are experiencing, generic prescription drugs are saving you money.

Read Blog
New White Paper: Nitrosamines

The generics industry is eager to work with FDA to adopt a balanced risked-based approach to addressing the concerns around nitrosamines in medicines.

Read AAM White Paper
2020 Access & Savings in the U.S. Report

The 2020 Generic Drug & Biosimilars Access & Savings in the U.S. report details the economic benefit of generics and biosimilars to America’s patients. The findings reinforce the outsized importance of the industry delivering lifesaving & health-managing meds.

Read Press Release
Plan to Secure Our Medicines

The U.S. generics and biosimilars industry, makers of 90% of our nation's prescription medicines, has a plan to #SecureOurMeds. We already produce billions of doses domestically and our plan ensures continued patient access through COVID and beyond.
Watch Video
Securing the U.S. Rx Supply Chain

The generic drug industry in the U.S. can expand domestically to increase national security, lessen dependence on any single country and create more jobs. Learn about our plan.

View Blueprint
Industry Response to COVID-19

The coronavirus (COVID-19) pandemic is disrupting everyday life around the world and imposing unprecedented stress on our health care system. Here are some responses and resources from the U.S. generics and biosimilars industry.

Learn More

Working to leave a positive impact on...

Industry

We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More

People

We measure our success as an industry by the lives we impact. We work to protect the low cost of current drugs and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More

Policy

We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable medicines. Learn More

About Us

The Association for Accessible Medicines improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Recent Updates

Oct 20, 2020 | Sara Skubikowski

Adding up the Generic Savings for Americans with Cancer and Other Conditions

Biosimilars patient Jeni, 35, from Santa Clarita, CA

Oct 15, 2020 | Erica Klinger

Jeni Got Her Life Back, Thanks to a Biosimilar

Video

Oct 8, 2020 | Erica Klinger

Jeni's Story — Biosimilars Savings

Medicaid Generics Penalty

Oct 7, 2020 | Rachel Schwartz

AAM Statement on the Introduction of the Protecting Access to Affordable Medicines Act of 2020

Nitrosamines: An Industry Position Paper Based on Risk

Oct 6, 2020 | Erica Klinger

White Paper: Nitrosamines — An Industry Position Paper Based on Risk

Oct 5, 2020 | Ericka Nguyen

Generic Drugs and Biosimilars Secure Big Savings for U.S. Patients